Health Care • Biotechnology: Pharmaceutical Preparations
$29.95 ▲ +0.50
(+1.70%)
MKT CAP: $170.71B • VOL: 34.26M
52W L $24 52W H $31
PFE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $62.58B | $63.63B | $50.91B |
| YoY Revenue Growth % | -1.6% | +25.0% | — |
| Gross Profit | $46.51B | $45.78B | $22.40B |
| Gross Margin % | 74.3% | 71.9% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $9.17B | $9.48B | $2.50B |
| Operating Margin % | 14.7% | 14.9% | 4.9% |
| Net Income (GAAP) | $7.77B | $8.03B | $2.12B |
| EBITDA (Normalized) | $11.27B | $11.80B | $4.33B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $11.70B | $12.74B | $8.70B |
| Capital Expenditures (CapEx) | $2.63B | $2.91B | $2.29B |
| Free Cash Flow (FCF) | $9.07B | $9.84B | $6.41B |
| FCF Margin % | 14.5% | 15.5% | 12.6% |
| Return on Invested Capital (ROIC %) | 4.9% | 5.2% | 3.5% |
| Cash & Short-Term Equivalents | $1.14B | $1.04B | $10.33B |
| Total Debt (Short + Long Term) | $61.64B | $57.41B | $21.97B |
| Total Stockholders' Equity | $86.48B | $88.20B | $45.07B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PFE.